Discovery of Novel Dual Small-Molecule Inhibitors Targeting SHP2 and NAMPT for Overcoming Resistance to Allosteric SHP2 Inhibition

  • J Med Chem. 2026 Jul 9;69(13):15510-15530. doi: 10.1021/acs.jmedchem.6c00353.
Kaizhen Wang  1  2 ,  Yijiao Liu  1 ,  Zhiyi Zhang  1 ,  Yingxin Hu  1 ,  Yuhua Zhong  1 ,  Sheng Jiang  1 ,  Xiangyu Zhang  1 ,  Kuojun Zhang  1 ,  Tianyu Wang  1
Affiliations
  • 1. School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • 2. School of Biomedical Engineering, Tsinghua University, Beijing 100084, China.
PMID: 42324937 DOI: 10.1021/acs.jmedchem.6c00353
Abstract

Inhibition of the Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) represents a promising therapeutic strategy for Cancer. However, resistance to SHP2 inhibition, mediated by multiple mechanisms, has limited the clinical efficacy of SHP2 Inhibitor monotherapy. Herein, we identified that nicotinamide phosphoribosyltransferase (NAMPT) inhibition could potentially overcome resistance to SHP2 inhibition in tumor cells. Compound A4 was identified as the most potent dual inhibitor targeting SHP2 and NAMPT, exhibiting high inhibitory activity against both SHP2 and NAMPT. A4 effectively inhibited proliferation in SHP099-insensitive tumor cell lines and reversed programmed cell death ligand 1 (PD-L1)-mediated immunosuppression. Furthermore, A4 displayed significant in vivo antitumor efficacy in an MDA-MB-231 mouse model and strongly promoted in vivo antitumor immunity in a 4T1 mouse model. Our results identified A4 as a promising dual SHP2 and NAMPT Inhibitor, providing a novel therapeutic strategy for overcoming resistance to allosteric SHP2 inhibition.

Products